Proliferation and directed migration of vascular cells are key components in vascular diseases such as atherosclerosis and restenosis following percutaneous transluminal coronary angioplasty. However, the precise cellular and molecular mechanisms involved in the control of vascular cell proliferation or migration at the tissue level remain largely undefined. Molecules contributing to these processes are elaborated by distinct cell types and act in both autocrine and paracrine modes. They include two broad classes, polypeptide growth factors and vasoactive G-protein-coupled receptor (GPCR) agonists. Examples of the former, such as platelet-derived growth factor, bind to and activate cell surface receptor tyrosine kinases, initiating intracellular biochemical signaling pathways associated with cell proliferation or migration. In contrast, recent evidence suggests that vasoactive GPCR agonists (e.g. angiotensin II, endothelin-1, alpha-thrombin) elicit cell growth indirectly by inducing the production of autocrine or paracrine factors in vascular cells. Recent studies have identified activin A as a novel component of conditioned medium obtained from GPCR agonist-stimulated vascular smooth muscle cells (SMCs). Although activin A alone only weakly stimulated rat aortic SMC DNA synthesis, it demonstrated a potent co-mitogenic effect in combination with either epidermal growth factor (EGF) or heparin binding EGF-like growth factor in these cells, increasing DNA synthesis by up to 5- and 4-fold respectively. Furthermore, in a rat carotid-injury model, activin A mRNA was upregulated within 6 h after injury, followed by increases in immunoreactive protein detected in the expanding neointima 7 to 14 days later. Taken together, these results indicate that activin A is a common vascular SMC-derived growth factor induced by vasoactive agonists that may, either alone or in combination with other factors, contribute to fibroproliferative vascular diseases.

This article has been cited by other articles:

				K. Fu, M. J. Corbley, L. Sun, J. E. Friedman, F. Shan, J. L. Papadatos, D. Costa, F. Lutterodt, H. Sweigard, S. Bowes, et al. SM16, an Orally Active TGF-{beta} Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 665 - 671. [Abstract] [Full Text] [PDF]

				K. L. Hamilton, L. Lin, Y. Wang, and A. A. Knowlton Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression Physiol Genomics, January 17, 2008; 32(2): 254 - 263. [Abstract] [Full Text] [PDF]

				L. Carta, L. Pereira, E. Arteaga-Solis, S. Y. Lee-Arteaga, B. Lenart, B. Starcher, C. A. Merkel, M. Sukoyan, A. Kerkis, N. Hazeki, et al. Fibrillins 1 and 2 Perform Partially Overlapping Functions during Aortic Development J. Biol. Chem., March 24, 2006; 281(12): 8016 - 8023. [Abstract] [Full Text] [PDF]

				J. Borawski, B. Naumnik, and M. Mysliwiec Activin A/Follistatin System: Another Link to Heparin-induced Osteoporosis? Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 191 - 192. [PDF]

				C. W. Brown, L. Li, D. E. Houston-Hawkins, and M. M. Matzuk Activins Are Critical Modulators of Growth and Survival Mol. Endocrinol., December 1, 2003; 17(12): 2404 - 2417. [Abstract] [Full Text] [PDF]

				B. C. Berk Vascular Smooth Muscle Growth: Autocrine Growth Mechanisms Physiol Rev, July 1, 2001; 81(3): 999 - 1030. [Abstract] [Full Text] [PDF]